Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

Charles E. Geyer

Research output: Contribution to journalEditorialpeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer'. Together they form a unique fingerprint.